trial results of vemurafenib, cobimetinib and ldh as a predictive marker in braf-mutated melanoma
Published 7 years ago • 314 plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
4:05
vemurafenib and cobimetinib in patients with braf-mutated melanoma
-
3:08
os rates and prognostic categories for braf-mutated melanoma when treated with combination therapy
-
2:25
biomarker analysis of cobrim: combined vemurafenib and cobimetinib for braf-mutated melanoma
-
3:33
cobimetinib plus vemurafenib for advanced braf-mutated melanoma
-
6:36
imspire 150: atezolizumab, cobimetinib and vemurafenib in untreated patients with brafv600 mutat...
-
2:24
biomarker analysis of cobrim: phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma
-
1:30
what to do with braf-mutant melanoma patients who have a poor prognosis?
-
1:03
dr. chapman describes the vemurafenib clinical trial
-
1:31
brim-3 trial in melanoma: prognostic factors of overall survival and the issue of salvage therapies
-
6:48
vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma
-
4:15
vemurafenib in combination with the mek inhibitor, gdc-0973 in brafv600 mutation pos melanoma
-
2:29
braf mutated melanoma: targeted or immunotherapy?
-
0:51
dr. mcarthur discusses subpopulation data from cobrim trial in advanced melanoma
-
6:22
vemurafenib in patients with braf600 mutation–positive metastatic melanoma
-
2:47
overall survival results for encorafenib plus binimetinib in braf-mutant melanoma
-
7:58
regulatory approvals for vemurafenib/cobimetinib, necitumumab, and elotuzumab
-
4:46
finding the faulty braf gene - cancer research uk
-
1:01:29
new rules for sequential care in braf-mutated melanoma
-
1:34
study of vemurafenib combined with a mek inhibitor